ARCT Long Call Strategy

ARCT (Arcturus Therapeutics Holdings Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

ARCT (Arcturus Therapeutics Holdings Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $234.8M, a beta of 2.43 versus the broader market, a 52-week range of 5.85-24.17, average daily share volume of 464K, a public-listing history dating back to 2013, approximately 174 full-time employees. These structural characteristics shape how ARCT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.43 indicates ARCT has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on ARCT?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current ARCT snapshot

As of May 15, 2026, spot at $7.47, ATM IV 77.20%, IV rank 16.32%, expected move 22.13%. The long call on ARCT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on ARCT specifically: ARCT IV at 77.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a ARCT long call, with a market-implied 1-standard-deviation move of approximately 22.13% (roughly $1.65 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ARCT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ARCT should anchor to the underlying notional of $7.47 per share and to the trader's directional view on ARCT stock.

ARCT long call setup

The ARCT long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ARCT near $7.47, the first option leg uses a $7.47 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ARCT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ARCT shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$7.47N/A

ARCT long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

ARCT long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on ARCT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on ARCT

Long calls on ARCT express a bullish thesis with defined risk; traders use them ahead of ARCT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

ARCT thesis for this long call

The market-implied 1-standard-deviation range for ARCT extends from approximately $5.82 on the downside to $9.12 on the upside. A ARCT long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ARCT IV rank near 16.32% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ARCT at 77.20%. As a Healthcare name, ARCT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ARCT-specific events.

ARCT long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ARCT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ARCT alongside the broader basket even when ARCT-specific fundamentals are unchanged. Long-premium structures like a long call on ARCT are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ARCT chain quotes before placing a trade.

Frequently asked questions

What is a long call on ARCT?
A long call on ARCT is the long call strategy applied to ARCT (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ARCT stock trading near $7.47, the strikes shown on this page are snapped to the nearest listed ARCT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ARCT long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ARCT long call priced from the end-of-day chain at a 30-day expiry (ATM IV 77.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ARCT long call?
The breakeven for the ARCT long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ARCT market-implied 1-standard-deviation expected move is approximately 22.13%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on ARCT?
Long calls on ARCT express a bullish thesis with defined risk; traders use them ahead of ARCT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current ARCT implied volatility affect this long call?
ARCT ATM IV is at 77.20% with IV rank near 16.32%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related ARCT analysis